AHA: Variation seen in rates of SGLT2i rx for heart failure, LVEF >40 percent
From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) greater than 40 percent, according to […]